Critics Say Cal's Genetic Tests Ignore 'Asian Flush' Risks
By Jeremy Hsu,
LiveScience
| 08. 05. 2010
Berkeley's incoming freshmen face the unprecedented choice of whether to take part in a genetic testing program this fall. But the students who volunteer for the controversial new test may get more than they bargained for if it turns up a gene deficiency responsible for what is known as "the Asian flush."
The gene has complex health implications that go beyond the surface symptom of a red face after downing an alcoholic drink or two. Even social drinkers are at higher risk of developing deadly esophageal cancer if they have a deficient version of the aldehyde dehydrogenase 2 (ALDH2) gene, according to years of research.
That knowledge seems missing so far from the University of California-Berkeley's education initiative about genetic testing and the future of personalized medicine, called "Bring Your Genes to Cal." The program gives the new class of freshmen students the choice of submitting cheek swab samples to test confidentially for variants of three specific genes. One of them is ALDH2.
"Yeah, we purposefully chose three genes that are not disease-associated," said Mark Schlissel, a Berkeley dean of...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
